Show simple item record

dc.contributor.editorRibatti, Domenico
dc.date.accessioned2023-04-05T13:01:03Z
dc.date.available2023-04-05T13:01:03Z
dc.date.issued2023
dc.identifierONIX_20230405_9783036569161_238
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/98959
dc.description.abstractTumor progression is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors. Inflammatory infiltration contributes to tumor progression and metastatic process, and there are many reports of associations between tumor inflammatory infiltration, progression and prognosis. New therapeutic approaches have been developed with the aim to control tumor progression through the targeting of different components of the tumor microenvironment. This reprint will be useful for anyone who wants to learn about cancer: professors and students at universities, scientists at research institutes, biotechnology, and pharmaceutical labs, and lawyers trying to understand the patent literature.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncologyen_US
dc.subject.otherRBP4
dc.subject.othermetastasis
dc.subject.otherbreast cancer
dc.subject.otherangiogenesis
dc.subject.otherendothelial dysfunction
dc.subject.otherSTAT3
dc.subject.otherVEGF
dc.subject.otherendothelin-1
dc.subject.otherresveratrol
dc.subject.othergemcitabine
dc.subject.otherendoglin
dc.subject.otherERKs
dc.subject.othermicrovessel growth
dc.subject.otherlung cancer
dc.subject.othercancer
dc.subject.otheranticancer
dc.subject.otherDLBCL
dc.subject.othertumor microenvironment
dc.subject.othercell adhesion mediated drug resistance
dc.subject.othertumor progression
dc.subject.otherVEGFR
dc.subject.otheranti-angiogenesis
dc.subject.otheranti-angiogenic agents
dc.subject.otherimmunosuppression
dc.subject.otherimmunotherapy
dc.subject.otherimmune-checkpoint inhibitors
dc.subject.othercombination therapy
dc.subject.othertumor angiogenesis
dc.subject.otherendothelium
dc.subject.othermicroenvironment
dc.subject.othermultiple myeloma
dc.subject.otheradhesion molecules
dc.subject.otherimmune-checkpoint inhibitor
dc.subject.othertumor-derived exosomes
dc.subject.othersmall extracellular vesicles
dc.subject.otherfeline mammary carcinoma
dc.subject.otherVEGF-A
dc.subject.otherVEGFR-1
dc.subject.otherVEGFR-2
dc.subject.othernon-invasive biomarkers
dc.subject.otherselectins
dc.subject.otherE-selectin
dc.subject.otheruproleselan
dc.subject.otheradrenal fetal cortex
dc.subject.otheradrenocortical tumors
dc.subject.otheradrenocortical carcinoma
dc.subject.otheranti-angiogenic drugs
dc.subject.otherbFGF
dc.subject.otheranti-angiogenic therapy
dc.subject.otherresistance
dc.subject.othervascular permeability
dc.subject.otherdrug delivery system
dc.subject.othermicrobeam radiation therapy (MRT)
dc.subject.otherChicken Chorioallantoic Membrane (CAM)
dc.subject.otherU-87 Glioblastoma
dc.subject.otherginsenoside Rg3
dc.subject.otherresponse surface methodology
dc.subject.otheroptimisation
dc.subject.otherepimer
dc.subject.otherlong pentraxin 3
dc.subject.otherFGF/FGFR system
dc.titleAngiogenesis in Cancers
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-6917-8
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036569161
oapen.relation.isbn9783036569178
oapen.pages274
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/